Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Medical Therapy and Birth Outcomes in Women With Crohn's Disease

What Should We Tell Our Patients?

Friedman, Sonia, M.D.

American Journal of Gastroenterology: July 2007 - Volume 102 - Issue 7 - p 1414–1416
ORIGINAL CONTRIBUTION: Editorial
Buy

It is not surprising that women with inflammatory bowel disease (IBD) have a greater risk of an adverse pregnancy outcome. Although it is ideal to be in remission during conception and pregnancy, women often flare during this critical time. Paradoxically, while pregnant, women often stop the medications that have worked so well to maintain remission due to the fear that these drugs may harm the fetus. Many women with IBD find it especially difficult to continue 6-mercaptopurine (6-MP) and azathioprine (AZA) during pregnancy. There have been a number of studies of IBD and pregnancy but none have successfully separated out the effects of disease activity and drug therapy on pregnancy outcomes. The study by Norgard et al. in this issue of the American Journal of Gastroenterology is the first to combine the power of two national data registries of hospitalizations, outpatient visits, and births with a national prescription database. The authors have detailed information on 900 babies born to mothers with Crohn's disease as well as information on every IBD drug prescribed during pregnancy from 1996 to 2004. The worrisome results here are the greater risk of preterm birth and congenital abnormalities among patients prescribed AZA/6-MP throughout their pregnancies. However, although the authors have accurate information on drug exposure during pregnancy, their measures of disease activity cannot be as accurate due to the nature of this database study. Only a prospective pregnancy registry of IBD patients can adequately differentiate the effects of disease activity and medication use on adverse pregnancy outcomes.

Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts

Reprint requests and correspondence: Sonia Friedman, M.D., Brigham and Women's Hospital, Gastroenterology Division ASBII, 75 Francis Street, Boston, MA 02115.

Received January 16, 2007; accepted February 10, 2007.

© The American College of Gastroenterology 2007. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website